Auryxia Approval History
FDA Approved: Yes (First approved September 5, 2014)
Brand name: Auryxia
Generic name: ferric citrate
Dosage form: Tablets
Company: Keryx Biopharmaceuticals, Inc.
Treatment for: Hyperphosphatemia of Renal Failure, Anemia Associated with Chronic Renal Failure
Auryxia (ferric citrate) is a phosphate binder indicated for the control of serum phosphorus levels in dialysis patients; and an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease who are not on dialysis.